ArticleBMC pharmacology & toxicology2025
Preparation and characterization of Lactobacillus rhamnosus, Lactobacillus casei, glycyrrhizin, vitamin-D3, and citric acid-loaded mucoadhesive pectin microparticles for the management of dental caries.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Host-microbiome-immune disequilibrium in oral disease: mechanisms, dysbiosis, and precision therapeutics.Frontiers in immunology · 2026Review
- Postbiotics and phage synergy in precision oral microbiome engineering: systems biology strategies targetingFrontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDental caries, a prevalent oral disease, results from bacterial biofilm formation and enamel demineralization, leading to tooth decay and associated complications. Conventional treatments face challenges such as poor drug bioavailability and antibiotic resistance.
objectivesThis study aims to develop a mucoadhesive localized drug delivery system (LDDS) incorporating Lactobacillus rhamnosus, Lactobacillus casei, glycyrrhizin (GL), citric acid (CA), and pectin (PC) to enhance antimicrobial, anti-inflammatory, and antioxidant properties for effective dental caries management.
methodsMicroparticles were synthesized via ionic gelation and characterized using Scanning Electron Microscopy (SEM), X-ray Diffraction (XRD), Differential Scanning Calorimetry (DSC), and Fourier-transform Infrared Spectroscopy (FTIR), etc.
resultsIn vitro assays, including antimicrobial (agar well diffusion, MIC, MBC), anti-biofilm, and anti-inflammatory (cytokine analysis), demonstrated significant antibacterial efficacy against S. aureus and S. mutans with notable reductions in inflammatory cytokines (IL-6, TNF-α, IL-1β) and increased IL-10 expression. The formulation also exhibited strong antioxidant potential in DPPH scavenging assays. In vivo studies on Wistar rats confirmed prolonged retention in the oral cavity and effective antimicrobial and anti-inflammatory activity, further supported by histopathological analysis. The findings indicate that the developed microparticles offer a promising alternative for dental caries treatment by ensuring sustained drug release, improved bioavailability, and enhanced therapeutic outcomes.
conclusionThis study underscores the potential of probiotic-based mucoadhesive drug delivery systems in oral health management. It highlights their role in reducing reliance on conventional antibiotics, mitigating bacterial resistance, and improving patient compliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.